|
A phase II study of larotrectinib for children with newly diagnosed solid tumors and relapsed acute leukemias harboring TRK fusions: Children’s Oncology Group study ADVL1823. |
| |
|
Consulting or Advisory Role - Bayer; Lilly; Loxo; Novartis |
Research Funding - Abbvie (Inst); Amgen (Inst); Atara Biotherapeutics (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Jubilant Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); Novartis (Inst); Novella Clinical (Inst); Pfizer (Inst); SERVIER (Inst) |
| |
|
No Relationships to Disclose |
| |
|
Patents, Royalties, Other Intellectual Property - U.S. patent based on Ph.D. research in glioblastoma (I) |
| |
|
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Curis (Inst); Eisai (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Salarius Pharmaceuticals (Inst); Turning Point Therapeutics (Inst) |
Travel, Accommodations, Expenses - Roche/Genentech; Salarius Pharmaceuticals |
(OPTIONAL) Uncompensated Relationships - Ymabs Therapeutics Inc |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Cor2Ed (Inst) |
Consulting or Advisory Role - Bayer (Inst) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Janssen |
| |
|
No Relationships to Disclose |
| |
|
Employment - Acceleron Pharma (I); Mersana (I); Shire (I) |
Stock and Other Ownership Interests - Acceleron Pharma (I); Mersana (I); Shire (I) |
Research Funding - Gradalis |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - Ignyta (Inst); Novartis (Inst) |
Other Relationship - Helsinn Therapeutics |
| |
|
No Relationships to Disclose |